myelodysplastic syndromes (MDS) | Page 4 | Aplastic Anemia & MDS International Foundation

myelodysplastic syndromes (MDS)

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes

Author(s): 
Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF.
Primary Author: 
Komrokji RS
Journal Title: 
Clin Lymphoma Myeloma Leuk
Original Publication Date: 
Mar 2019
BACKGROUND:
Bone Marrow Diseases: 

Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial.

Author(s): 
Garcia-Manero G, Almeida A, Fenaux P, Gattermann N, Giagounidis A, Goldberg SL, Ozawa K, Weaver J, Santini V.
Primary Author: 
Garcia-Manero G
Journal Title: 
Clin Lymphoma Myeloma Leuk
Original Publication Date: 
Dec 2018
BACKGROUND:
Bone Marrow Diseases: 

Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria.

Author(s): 
Escalante CP, Chisolm S, Song J, Richardson M, Salkeld E, Aoki E, Garcia-Manero G.
Primary Author: 
Escalante CP
Journal Title: 
Cancer Med
Original Publication Date: 
Feb 2019
BACKGROUND:

2019 March for Marrow 5K Run & Walk Los Angeles

Come celebrate the 10th Annual March for Marrow Los Angeles with Honorary Chair Connie Britton. Our 5K and Walk have the distinction of taking place along the beautiful stretch of shoreline that is part of the Long Beach Shoreline Marina. With the iconic Queen Mary in the background, the course is scenic, flat, and regardless of weather, ideal for beating one's personal best.

Event Date: 
Sat, 04/27/2019 -
6:30am to 12:00pm
Community Event Type: